Zobrazeno 1 - 10
of 29
pro vyhledávání: '"cc-122"'
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 13, Pp 61-71 (2021)
Yiming Cheng,1 Jian Chen,2 Michael Pourdehnad,3 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, NJ, USA; 2Non-Clinical Research & Development, Bristol Myers Squibb, Summit, NJ, USA; 3Early Clinical Develop
Externí odkaz:
https://doaj.org/article/057f02a8d2314ce997e30bc610a5447f
Publikováno v:
Biomarker Research, Vol 8, Iss 1, Pp 1-8 (2020)
Abstract Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies. Recent studies
Externí odkaz:
https://doaj.org/article/38d2f75ab6fc470cb3c86a1f6a91dd79
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 8, Pp 117-125 (2016)
Yan Li, Leonidas N Carayannopoulos, Michael Thomas, Maria Palmisano, Simon Zhou Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA Abstract: CC-122 hydrochloride is a novel pleiotropic pathway modifier compound
Externí odkaz:
https://doaj.org/article/93c0b24e1f2a45bea58007173b9899bd
Autor:
Jacques, Vincent, Czarnik, Anthony W., Judge, Thomas M., Van der Ploeg, Lex H. T., DeWitt, Sheila H.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 2015 Mar . 112(12), E1471-E1479.
Externí odkaz:
https://www.jstor.org/stable/26462177
Autor:
Patrick Hagner, Yumi Ogaki, Harumi Kato, Takaaki Chou, Sachiko Seo, Takayuki Hirose, Kiyohiko Hatake, Kazuhito Yamamoto, Toshihiko Doi, Yasuhito Terui, Hiroshi Fujimoto, Michael Pourdehnad
Publikováno v:
Cancer Science
Non‐Hodgkin lymphoma (NHL) treated with chemoimmunotherapy has limited efficacy in some patients, resulting in relapsed or refractory disease. Avadomide (CC‐122) is a novel cereblon‐binding agent that exhibits antilymphoma and immune‐modulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a650a14949cf2dbd0f6bb45c5e924154
https://doi.org/10.1111/cas.14704
https://doi.org/10.1111/cas.14704
Publikováno v:
Clinical Pharmacology : Advances and Applications
Yiming Cheng,1 Jian Chen,2 Michael Pourdehnad,3 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Summit, NJ, USA; 2Non-Clinical Research & Development, Bristol Myers Squibb, Summit, NJ, USA; 3Early Clinical Develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01a60a617a607922aef4c64b153f5ee2
https://www.dovepress.com/population-pharmacokinetics-of-cc-122-peer-reviewed-fulltext-article-CPAA
https://www.dovepress.com/population-pharmacokinetics-of-cc-122-peer-reviewed-fulltext-article-CPAA
Publikováno v:
Biomarker Research
Biomarker Research, Vol 8, Iss 1, Pp 1-8 (2020)
Biomarker Research, Vol 8, Iss 1, Pp 1-8 (2020)
Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies. Recent studies showed th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098164a66f366e2ded03e2988a916a89
https://pubmed.ncbi.nlm.nih.gov/31938543
https://pubmed.ncbi.nlm.nih.gov/31938543
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Do, Priscilla
Immune suppression is a hallmark of cancer that has gained recent unprecedented attention following dramatic responses with new immune based therapies. Many therapeutic strategies are employed to reverse suppression and utilize our natural biological
